Rating Card

premiumPremium content

Unlock Expert's Rating and Top Picks Portfolio

Curated by Michael O'Reilly since 2020
1550+ opinions with 4.81 rating (one of the best performing expert)

Latest Top Picks

Stock Opinions by Chris Blumas

Most recent Opinions go here

Be up to date, don’t miss your chance.

COMMENT

Today, core US inflation is up which translates to positive news. Tariffs were supposed to impact this July number, but is up only slightly from June. Some research says that a third to two-thirds of the tariff impact is being absorbed by companies instead of being passed onto consumers, such as inventory build-up. But in time, companies will inevitably pass the tariff impact onto consumers. However, credit car delinquencies show consumers are growing strained. We still have to watch the data. It could take up to 12 months before we see the full impact of tariffs onto consumers. The US Fed between announcements issues forward guidance, which is a softer way to make a rate announcement. Trump is strongly pressuring the Fed to cut rates.  

DON'T BUY

Prefers Canadian banks for their dividends. For instance, BNS is undervalued and pays a high dividend and trades at a low PE. There's room for the PE to expand. People buy foreign banks for the dividend, but you have to pay a withholding tax.

BUY
Question about Banco Santander

Prefers Canadian banks for their dividends. For instance, BNS is undervalued and pays a high dividend and trades at a low PE. There's room for the PE to expand. People buy foreign banks for the dividend, but you have to pay a withholding tax.

BUY ON WEAKNESS

Are facing some issues. As the minimum wage has risen, their labour costs have too. Also, pre-tariffs, they faced labour shortages. After tariffs, the car parts they used possibly faced tariffs. Is defensive, but the valuation is rich. Is cash-flow positive.

HOLD

The Union Pacific-Norfolk merger in the US more likely to happen under this administration than the last and will create more competition among all railroads, including CN. The industry is attractive, because there are few companies, but the downside is the lack of growth and the rails are economically sensitive. They sold off this year under Trump's tariffs. Sit tight, if you own it. Trades at a reasonably 17x PE. He prefers CP for its network across the US and Canada, but it will take time to return to favour.

BUY

Like GS-N, it's the dominant bank in its country, and trades at a premium to peers, but deserves the premium because they've expanded into the lucrative wealth management area. They don't suffer problems in US retail banking like some peers; RY exited that decades ago. The forward PE of 13-14x is slightly higher than historic and this sector, but is justified through earnings growth.

DON'T BUY

Has done very well since its spin-off years ago. Any insurer can generate earnings. If TSU revives their reserves down the road it will wipe out any earnings they've accumulated and any retained capital in that business. In insurance, Berkshire-Hathaway and Fairfax. Insurance stocks are more expensive, because they are counter-cyclical and the money that's flowing into this space have increased the valuations.

HOLD

A stable, dependable business with a good footprint in the US that will allow growth. It has room to run. The valuation is below peers and debt is much better. Can use a stop loss to lock in your gains. Or sit tight.

PAST TOP PICK
(A Top Pick Aug 14/24, Up 43%)

A core holding, though would wait for a pullback to add more. The underlying business is private equity. Given potential changes in 401K plans in the US, there will be more demand for private equity. Large players like this are well-positioned. Has seen strong earnings growth the past year and multiples expansion. This is one of the best compounders.

PAST TOP PICK
(A Top Pick Aug 14/24, Up 21%)

Pharma is in the penalty box, but medical devices are not (so far). Organic growth in the core business is nearly 10%, strong. They enjoy massive demographic support. The PE is around a low 20x PE. Has strong growth. Wait for a pullback to enter.

PAST TOP PICK
(A Top Pick Aug 14/24, Up 31%)

Are totally different from MFC and SLF which have businesses in China and India. GWO instead has business in Europe where they can buy attractive companies. Is an income stock. Trades at only 11x PE, with strong growth. A core holding. Pays a dividend around 5%.

BUY

The worst-performing infrastructure-pipeline name in the short term. Are some issues with an asset in Canada where the regulated pricing has been set lower. That's holding this stock back. A well-run business with good assets, but has volatility. It has more outlets for growth vs. peers like ENB. Can buy this for the dividend and wait. The PE is low, and will always trade at a discount to peers, because less of its cash flow is regulated.

BUY

It's a massive positive they won't do the 7-11 deal--too big without issuing equity. Are top-notch buyers, though. The overhang now is economic uncertainty from a weaker consumer. Is a strong company and compounder.

PARTIAL SELL

Is fairly valued. Has returned 59% over 5 years. The problem is that if the fertilizer price gets too high, farmers delay buying it. The PE is reasonable, though. It's had a good run the past 12 months.

BUY ON WEAKNESS

This type of company is out of his wheelhouse. He looks at cash flow; SHOP's free cash flow is too expensive. SHOP has been growing like gangbusters. He watches it, because it's significant in Canada. The changes in US taxation did not impair SHOP, surprisingly. Their business keeps going very well. Is a momentum name, but growth could slow and the street could focus on its cash flow down the road. The PE is rich.

Showing 1 to 15 of 879 entries